Stay updated on Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial
Sign up to get notified when there's something new on the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page.

Latest updates to the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page
- Check3 days agoChange DetectedFooter now shows Revision: v3.3.3; HHS Vulnerability Disclosure link and older Revision: v3.3.2 have been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedMinor revision: updated from v3.2.0 to v3.3.2 and no changes to study details or content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check39 days agoChange DetectedRemoved the notice about government funding and potential delays. The page no longer displays operating status information.SummaryDifference0.4%

- Check53 days agoChange DetectedBetween the old and new screenshots, core trial information (title, conditions, eligibility criteria, endpoints, enrollment location, and contact) remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check81 days agoChange DetectedAdded a government funding lapse notice and a v3.2.0 version tag, replacing the prior v3.1.0.SummaryDifference5%

- Check88 days agoChange DetectedThe page now shows a new version (v3.1.0) and includes a contact/identifier entry, while the old version reference (v3.0.2) is removed.SummaryDifference0.1%

Stay in the know with updates to Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page.